Nishio Nobuhiro, Yagasaki Hiroshi, Takahashi Yoshiyuki, Muramatsu Hideki, Hama Asahito, Yoshida Nao, Kudo Kazuko, Kojima Seiji
Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Shouwa-ku, Nagoya, 466-8550, Japan.
Department of Pediatrics, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan.
Int J Hematol. 2009 May;89(4):409-413. doi: 10.1007/s12185-009-0302-9. Epub 2009 Apr 3.
Although the known clinical courses of non-severe aplastic anemia (NSAA) in children comprise spontaneous resolution, persistent NSAA, or progression to severe aplastic anemia (SAA), only a few published reports have indicated the outcome of transfusion-independent NSAA. We retrospectively evaluated the incidence and time of progression from transfusion-independent to transfusion-dependent NSAA or SAA. We reviewed the records of 70 children with acquired AA who were referred to our hospital between 1986 and 2006, and among them we found 22 patients who had transfusion-independent NSAA at diagnosis and were treated with supportive care alone until progression to transfusion-dependent AA. 22 patients were followed up for a median of 86 months (range, 11-198 months). The Kaplan-Meier estimates for progression-free survival were 62 +/- 12 and 22 +/- 13% at 60 and 120 months after diagnosis, respectively. None of the patients treated with supportive care alone improved hematologically. In conclusion, because the incidence of disease progression was high in patients with NSAA, a prospective randomized trial of early intervention with IST or observation alone until disease progression to SAA, followed by IST when the patients become transfusion-dependent is warranted.
尽管已知儿童非重型再生障碍性贫血(NSAA)的临床病程包括自发缓解、持续性NSAA或进展为重型再生障碍性贫血(SAA),但仅有少数已发表的报告指出了无需输血的NSAA的转归情况。我们回顾性评估了从无需输血的NSAA进展为需要输血的NSAA或SAA的发生率及时间。我们查阅了1986年至2006年间转诊至我院的70例获得性再生障碍性贫血患儿的记录,其中我们发现22例在诊断时为无需输血的NSAA且仅接受支持治疗直至进展为需要输血的再生障碍性贫血的患者。对22例患者进行了中位时间为86个月(范围11 - 198个月)的随访。诊断后60个月和120个月时无进展生存的Kaplan - Meier估计值分别为62±12%和22±13%。仅接受支持治疗的患者血液学均未改善。总之,由于NSAA患者疾病进展的发生率较高,有必要进行一项前瞻性随机试验,比较早期进行免疫抑制治疗(IST)干预或仅观察直至疾病进展为SAA,然后在患者需要输血时进行IST治疗的效果。